Search
United Therapeutics Corp
UTHRAdd to Watchlist
544.330USD
+6.030+1.12%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
22.95BMarket Cap
18.60P/E TTM
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Tyvaso DPI
1.29B
40.59%
Nebulized Tyvaso
585.70M
18.40%
Remodulin
526.80M
16.55%
Orenitram
496.90M
15.61%
Unituxin
226.80M
7.13%
Other
54.70M
1.72%
By RegionUSD
Name
Revenue
Proportion
United States
3.04B
95.42%
Rest of World
145.70M
4.58%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Tyvaso DPI
1.29B
40.59%
Nebulized Tyvaso
585.70M
18.40%
Remodulin
526.80M
16.55%
Orenitram
496.90M
15.61%
Unituxin
226.80M
7.13%
Other
54.70M
1.72%
